SYNPLOGEN
LIVE

Serial Number

79272215

Owner

Synplogen Co., Ltd.

Attorney

Kumiko Ide

Filing Date

Aug 22, 2019

Add to watchlist:

No watchlists yet
View on USPTO

SYNPLOGEN Trademark

Serial Number: 79272215 • Registration: 6115549

SYNPLOGEN is a trademark filed by Synplogen Co., Ltd. on August 22, 2019. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Synplogen Co., Ltd. (4 trademarks)

1-1 Rokkodai-cho,

Entity Type: 03

Trademark Details

Filing Date

August 22, 2019

Registration Date

August 4, 2020

Published for Opposition

May 19, 2020

Goods & Services

Research and development relating to DNA synthesis technology; technical advisory services and * providing * information technology consulting services relating to DNA synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, quality control for others, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; * providing * technical advisory services and information technology consulting services relating to genome synthesis technology; research and development, quality control for others, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection and research of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; * providing * technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; information technology services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; testing, inspection and research relating to medical treatment or medical technology with genome synthesis technology; * providing * information technology consulting services for testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testing, inspection or research on agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others for scientific research purposes; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; [ DNA sequence design services for scientific research purposes; ] research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research in the field of microorganisms; bacteriological research; biological research

Filing History

TEAS SECTION 71 RECEIVED
Apr 21, 2026 ES71
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Aug 4, 2025 REM3
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Feb 17, 2023 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 24, 2022 INPR
NEW REPRESENTATIVE AT IB RECEIVED
Jul 30, 2022 NREP
LIMITATION FROM THE IB EXAMINED AND ENTERED
Apr 25, 2022 LIME
CORRECTION UNDER SECTION 7 - PROCESSED
Apr 24, 2022 COC.
LIMITATION OF GOODS RECEIVED FROM IB
Feb 5, 2022 LIMG
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 12, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 25, 2020 FICS
FINAL DISPOSITION PROCESSED
Nov 25, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 4, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Aug 4, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 19, 2020 NPUB
PUBLISHED FOR OPPOSITION
May 19, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 29, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 13, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 23, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 23, 2020 CRFA
ASSIGNED TO LIE
Mar 19, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 12, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 31, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jan 31, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jan 31, 2020 CNRT
REFUSAL PROCESSED BY IB
Jan 17, 2020 RFNT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 14, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 14, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 14, 2020 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 2, 2020 RFCS
REFUSAL PROCESSED BY MPU
Jan 2, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 4, 2019 RFCR
NON-FINAL ACTION WRITTEN
Dec 3, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Nov 26, 2019 MAFR
ASSIGNED TO EXAMINER
Nov 22, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 22, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 21, 2019 REPR